Spearhead Capital Advisors, LLC Blueprint Medicines Corp Transaction History

Spearhead Capital Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$54.1 - $110.08 $269,959 - $549,299	-4,990 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$94.25 - $115.99 $22,997 - $28,301	244 Added 5.14%	4,990 $534,000
Q3 2021 Oct 27, 2021	BUY	$80.98 - $109.47 $19,597 - $26,491	242 Added 5.37%	4,746 $488,000
Q2 2021 Aug 10, 2021	BUY	$82.78 - $101.0 $45,115 - $55,045	545 Added 13.77%	4,504 $396,000
Q1 2021 Apr 28, 2021	BUY	$90.71 - $108.28 $359,120 - $428,680	3,959 New	3,959 $385,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.